Aortic stenosis is characterized both by progressive valve narrowing and the left ventricular remodeling response that ensues. The only effective treatment is aortic valve replacement, which is usually recommended in patients with severe stenosis and evidence of left ventricular decompensation. At present, left ventricular decompensation is most frequently identified by the development of typical symptoms or a marked reduction in left ventricular ejection fraction <50%.
B, for intervention in the most common scenariosymptomatic, severe aortic stenosis. However, intervention in asymptomatic patients with a reduction in ejection fraction <50% or an abnormal exercise test is only Level of Evidence: C (i.e., expert opinion) (15) .
The American College of Cardiology and American
Heart Association guidelines are largely in alignment (14) . This highlights the need for more robust data to better risk-stratify patients and optimize management strategies before the onset of symptoms and heart failure. (16, 17) . Attention has focused on myocardial fibrosis in particular, given its structurefunction correlation with heart failure and the fact that it can now be identified reliably and noninvasively with modern imaging techniques. This review will discuss the pathophysiology of myocardial fibrosis and left ventricular decompensation in aortic stenosis, the imaging techniques that can be used to detect it, and how these might be employed to track myocardial health and optimize the timing of AVR.
PATHOLOGY
It is useful to consider aortic stenosis as a disease of both the valve and the myocardium (4). In addition, the importance of arterial stiffness and systemic pulsatile arterial load cannot be underestimated in this elderly population (18, 19) . A detailed discussion of events within the valve is beyond the scope of this review (20) ; however, an understanding of the pathological factors driving the hypertrophic remodeling response and its subsequent decompensation are critical to understanding the rationale for myocardial fibrosis imaging (Central Illustration).
Progressive valve narrowing causes pressure overload of the left ventricle and triggers a hypertrophic response that maintains wall stress and left ventricular performance for many years. Over time, this process decompensates and patients transition from hypertrophy to heart failure, leading to adverse clinical outcomes. This evolution is complex but is closely related to the development of myocardial fibrosis, myocyte injury, and cell death. Furthermore, there is adverse remodeling of the extracellular matrix, with degradation and disruption of the matrix structure (21) . These changes are regulated by several factors, including the renin-angiotensin-aldosterone system, transforming growth factor beta, apoptosis signal-regulating kinase 1, and tissue inhibitor of metalloproteinase (22) (23) (24) : all potential targets for novel therapeutic interventions.
Two distinct myocardial fibrosis patterns have been described. Reactive interstitial fibrosis is diffuse and follows increased myofibroblast activity and collagen deposition that begins even in the early stages of aortic stenosis. Importantly, this diffuse fibrosis is reversible and has been demonstrated to regress following AVR (16). In contrast, replacement fibrosis appears to occur later and is irreversible (25) . Treibel et al. (26) recently demonstrated that patients with advanced disease undergoing AVR manifest a complex combined pattern of both replacement and diffuse fibrosis. Moreover, they observed a fibrosis gradient from the subendocardium to the midmyocardium, perhaps suggesting supply-demand ischemia as a contributing factor.
The degree of myocardial remodeling and fibrosis is closely related to hemodynamic markers of myocardial performance, such as end-diastolic pressure and ejection fraction (4). Moreover, multiple Bing et al.
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histological studies have now demonstrated an association between myocardial fibrosis at the time of AVR and both impaired recovery of left ventricular systolic function and poor long-term outcomes following valve replacement (17, (27) (28) (29) . Although it is certainly plausible that myocardial fibrosis might directly contribute to such outcomes, a causal
relationship is yet to be demonstrated.
IMAGING MODALITIES FOR THE ASSESSMENT OF MYOCARDIAL FIBROSIS
Although myocardial biopsy and histological analysis are still considered the gold standard assessments of myocardial fibrosis, they have several important limitations precluding their routine clinical application. Myocardial biopsy is an invasive procedure that carries an attendant risk of complications (30 Schematic of the left ventricular remodeling response in aortic stenosis, describing the transition from hypertrophy to fibrosis, heart failure, and cardiac death.
LGE is now well established and widely used as a method for detecting replacement myocardial fibrosis in a broad range of cardiovascular conditions such as ischemic cardiomyopathy, nonischemic dilated cardiomyopathy, cardiac sarcoidosis, cardiac amyloidosis, myocarditis, and hypertrophic cardiomyopathy (31) (32) (33) (34) (35) (36) (37) (38) . In each condition, replacement fibrosis detected by LGE serves as an independent and powerful predictor of mortality and adverse cardiovascular events.
LGE is also the most studied and best Bing et al.
Imaging and Impact of Myocardial Fibrosis in Aortic Stenosis F E B R U A R Y 2 0 1 9 : 2 8 3 -9 6 incremental value to valve assessments, comorbidity, and left ventricular ejection fraction (28, 41, (44) (45) (46) ( Table 2 ).
The poor prognosis associated with non-infarct
LGE appears to persist long after AVR is performed, in keeping with the irreversible nature of replacement fibrosis. In the largest study to date, the British
Society for Cardiovascular Magnetic Resonance Valve
Consortium performed comprehensive CMR assessments in over 650 patients with severe aortic stenosis just prior to SAVR or TAVR (46) . At a median followup of 3.6 years, LGE (present in 50% of patients) was a powerful independent predictor of all-cause Noninfarct LGE was also demonstrated to be an independent predictor of both all-cause and cardiovascular mortality.
LGE is reliable, well-validated, and easily inte- Fabry disease (48) , and has demonstrated significant prognostic power beyond that of LGE alone (53, 54) .
Although less robust, data is also emerging for native T 1 in aortic stenosis. Recent studies have demonstrated a correlation between native T 1 and both the degree of diffuse fibrosis on histology and the extent of ventricular remodeling on CMR (55-57) ( LGE appeared to be concordant with histology (88% with severe fibrosis had $2 positive segments; 89% with no fibrosis had no positive segments) and did not regress at 9 months post-AVR.
Azevedo et al. (28) 2010 28
Severe AS undergoing AVR 1.5-T LGE
28
LGE was present in 61%.
LGE correlated with histology (r ¼ 0.67; p < 0.001).
LGE was an independent predictor of all-cause mortality Baron-Rochette et al.
2014 154 Severe AS undergoing AVR 1.
5-T LGE -
LGE present in 29%.
LGE was an independent predictor of all-cause mortality (HR: 2.8; 95% CI: 1.1 to 6.9; p ¼ 0.025).
Rajesh et al. (81) 2017 109
Severe AS 1.
5-T LGE -
LGE present in 43%. Midwall LGE present in 31%.
LGE predicted heart failure/hospitalization and a fall in LVEF but did not predict mortality. 
12
LGE was present in 17 of 31 patients (from total cohort).
Only ECV% correlated with histology (r ¼ 0.79; p ¼ 0.011). 
1.5-T, 3-T iECV LGE
Midwall LGE was present in 26%.
LGE progressed from baseline and was most rapid in patients with more severe stenosis. In patients undergoing AVR, iECV reduced by 11% (4%-16%) but there was no change in LGE.
Lee et al. (58) 2018 127
Moderate or severe AS 3-T Native T 1 LGE MOLLI -LGE was present in 32.3%. Native T 1 was increased compared with control patients, with overlap. Native T 1 and LGE were independent predictors of poor prognosis. 
post-contrast (62). A key feature of myocardial
fibrosis is the deposition of excess collagen in the interstitial space and the subsequent expansion of the extracellular space. ECV% has therefore been investigated as a method for detecting diffuse myocardial fibrosis in a range of cardiovascular conditions including myocardial infarction, nonischemic cardiomyopathy, and aortic stenosis (63, 64) .
Current scanning techniques assume a dynamic equilibrium between blood and myocardium w10 to 15 mins after a bolus injection of contrast (65, 66) . A synthetic ECV% has also been described that derives hematocrit from the longitudinal relaxation rate of blood, obviating the need for blood sampling (67) Table 2) .
ECV% also demonstrates excellent scan-rescan reproducibility (59), while guidelines to standardize post-processing have been developed and recommend that areas of noninfarct LGE are included and areas of infarct LGE excluded from regions of interest in ECV% calculation (69) . However, data assessing the prognostic value of ECV% in aortic stenosis are limited, and overlap between disease groups is again observed. In addition, the effect of AVR on ECV% Bing et al.
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Imaging and Impact of Myocardial Fibrosis in Aortic Stenosis CT ¼ computed tomography; DCM ¼ dilated cardiomyopathy; HF ¼ heart failure; HFpEF ¼ heart failure with preserved ejection fraction; HFrEF ¼ heart failure with reduced ejection fraction; other abbreviations as in Table 2 .
research expands, this approach may offer clear advantages over LGE. For example, future investigation of antifibrotic therapies will require biomarkers to monitor myocardial health and treatment effects; T 1 mapping will be indispensable in this regard.
Further work to investigate the role of emerging CT techniques is also warranted, particularly as they may be more easily integrated into current clinical care pathways and workflows than CMR. There has also been early investigation of collagen-and elastin-specific CMR contrast agents, which may provide greater contrast to noise ratio compared with current GBCAs, but further advances in this field are awaited (73, 74 
